

20th EAHP congress. Hamburg, Germany



CP-095

EFECTIVIDAD DE KETOCONAZOL EN PACIENTES CON CANCER DE PROSTATA METASTASICO RESISTENTE A LA CASTRACION NO CANDIDATOS A QUIMIOTERAPIA

González-Bueno J¹, Calvo-Cidoncha E², Vega-Coca MD¹, Santos-Rubio MD¹, Sierra-Torres MI¹, Bautista-Paloma FJ¹. ¹Pharmacy Department. Virgen del Rocío Hospital; Sevilla ²Pharmacy Department. Virgen de Valme Hospital; Sevilla. Spain

Background

Ketoconazole (KT) has been extensively used in chemo-naive patients (mCRPC) with metastatic castration-resistant prostate cancer due to the absence of therapeutic alternatives.

Objective To determine the effectiveness of KT in chemo-naive patients with mCRPC.

Materials and Methods

Retrospective observational study

•Inclusion criteria: chemo-naive patients on therapy with ketoconazole during \geq 3 months for mCPRPC between 06/2010-06/2014 in a tertiary hospital.

•Exclusion criteria: < 3 months on therapy, patients with insufficient information in their medical records.

 Variables

 •Age

 •Baselline PSA

 •Baselline PSA

 •% PSA decrease from baseline to nadir

 •PSA-RR*^Υ at week 12

 •bPFS**^β

 *PSA response rate. **biochemical progression-free survival

 ^YDefined as a ≥50% PSA decline from baseline maintained for ≥3 weeks efinida en base a las recomendaciones del Prostate Cancer Clinical Trials Working Group (PCWG2).

 ^βDefined as the time between ketoconazole initiation and PSA (or radiologic) progression according to PCWG2 criteria.


•Statistical analysis: Means ± standard deviation or the median and the 25th-75th percentiles summarize results. Kaplan-Meier analysis was performed to determine the bPFS. Data analysis was performed using IBM SPSS Version 20.0.

Results

Twenty-eight patients (76±11 years) were included. The median baseline PSA was 29[14-89] ng/ml.


PSA change aftter starting KT

The % PSA decrease from baseline to nadir was 54%±29.



PSA-RR at week 12 was 31% (9 patients).

The mean time to achieve this reduction was 13±15 weeks.



<u>Median bPFS</u>

Patients with a baseline PSA declined after starting KT (n=23): 87[IC95%: 35-139] weeks. Patients with a ≥ 50% PSA decline at 12 weeks: median bPFS not reached at the time of data analysis.

Conclusions

- Approximately one third of patients treated with KT experienced rapid PSA declines close to those observed with abiraterone (37-42%).
- The PSA-RR, the significant bPFS, its low cost and the possibility of starting abiraterone after KT highlight KT as an alternative in chemo-naïve patients with mCRPC.